Regen BioPharma issues 40M shares to CEO and consultant for Phase I trial; shares vest on trial success

Regen BioPharma Inc

Issued 20M shares to CEO David Koos for services in planned Phase I trial of HemaXellerate; shares vest upon trial completion.
Issued 20M shares to consultant Dr. Harry Lander for same purpose; same vesting condition.
Total outstanding shares jump to 79,374,704 as of Oct 3, 2025, reflecting ~100% dilution from these grants.
Phase I trial targets drug-refractory aplastic anemia using autologous stromal vascular fraction from adipose tissue.
Shares are restricted and unregistered; vest only upon successful trial completion, otherwise forfeited.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.